ZA200103081B - Therapy for improving cognition. - Google Patents
Therapy for improving cognition. Download PDFInfo
- Publication number
- ZA200103081B ZA200103081B ZA200103081A ZA200103081A ZA200103081B ZA 200103081 B ZA200103081 B ZA 200103081B ZA 200103081 A ZA200103081 A ZA 200103081A ZA 200103081 A ZA200103081 A ZA 200103081A ZA 200103081 B ZA200103081 B ZA 200103081B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- substance
- atypical antipsychotic
- acetylcholinesterase inhibitor
- active ingredient
- Prior art date
Links
- 230000019771 cognition Effects 0.000 title claims description 10
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims description 28
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 26
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 24
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 21
- 206010012289 Dementia Diseases 0.000 claims description 18
- 208000024827 Alzheimer disease Diseases 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 230000002411 adverse Effects 0.000 claims description 13
- 229960003980 galantamine Drugs 0.000 claims description 12
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 12
- 208000028017 Psychotic disease Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229960001534 risperidone Drugs 0.000 claims description 11
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical group FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 8
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 230000006866 deterioration Effects 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical group FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 206010038743 Restlessness Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 229960003530 donepezil Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 229960003162 iloperidone Drugs 0.000 claims description 3
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 229960005017 olanzapine Drugs 0.000 claims description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229960004431 quetiapine Drugs 0.000 claims description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 3
- 238000009097 single-agent therapy Methods 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 229960000607 ziprasidone Drugs 0.000 claims description 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 3
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 description 5
- -1 for example Chemical class 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
THERAPY FOR IMPROVING COGNITION
The present invention is concerned with pharmaceutical compositions comprising a carrier and as first active ingredient an atypical antipsychotic agent (I) and as second ) active ingredient an acetylcholinesterase inhibitor (I), each in an amount producing a therapeutically beneficial effect in patients suffering from psychosis, or Alzheimer's disease or related dementias. Said therapeutically beneficial effect can be a synergistic effect on the cognitive functioning of patients suffering from Alzheimer‘s disease or related dementias, or the prevention of the further deterioration of cognition in said patients, or the reduction of adverse effects associated with the one of the active, ingredients by the other of the active ingredients.
Of particular interest is the use of an atypical antipsychotic agent (I) for the preparation of a medicament for reducing adverse effects associated with acetylcholinesterase inhibitors (II) in patients suffering from Alzheimer's disease or related dementias, such as nausea, vomiting, sweating, restlessness and insomnia. Especially interesting|is the use of an atypical antipsychotic agent (D) for the preparation of a medicament for improving sleep in patients suffering from Alzheimer's disease or related dementias while being treated with acetylcholinesterase inhibitors (II).
The present invention is concerned with a pharmaceutical composition comprising a carrier and as first active ingredient an atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor (II), each in an amount producing a therapeutically beneficial effect in patients suffering from psychosis, or Alzheimer's disease or related dementias. Said therapeutically beneficial effect can be a synergistic effect on the cognitive functioning of patients suffering from Alzheimer‘s disease or related dementias, or the prevention of the further deterioration of cognition in said patients, or the reduction of adverse effects associated with the one of the active ingredients by the other of the active ingredients.
The atypical antipsychotic (I) is selected from risperidone, 9-hydroxyrisperidone ora
Cio-20 alkanoic acid ester thereof, olanzapine, quetiapine, iloperidone or ziprasidone, and the acetylcholinesterase inhibitor (0) is selected from galantamine, rivastigmine or donepezil, or therapeutically active acid addition salt form of any of the foregoing. Said salts comprise salt forms which the active ingredients (I) and (II) are able to form with appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, : ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, gamibo- salicylic, pamoic and the like acids. For example, galantamine may conveniently be used as the (1:1) hydrobromide salt.
C10-20alkanoic acids are selected from the group consisting of decanoic (capric), undecanoic, dodecanoic (lauric), tridecanoic, tetradecanoic (myristic), pentadecanoic, hexadecanoic (palmitic), heptadecanoic, octadecanoic (stearic), nonadecanoic and eicosanoic acid. Due to their limited aqueous solubility, it was generally believed that the esters had to be suspended into oils. The ester having a C15 (pentadecyl) chain and the active ingredient corresponding thereto being the 9-hydroxyrisperidone palmitate ester was found to be the superior ester from a pharmacokinetic, as well as from a tolerance point of view. : 15
Preferably, the amount of each of the active ingredients is equal to or less than'that which is approved in monotherapy with said active ingredient.
Most preferred are compositions wherein the atypical antipsychotic (I) is risperidone : and the acetylcholinesterase inhibitor (II) is galantamine, in particular as galantamine hydrobromide. In said compositions, the amount of risperidone is 0.5, 1, 2, 4, or 6 mg and that of galantamine (as base) is 8, 16, 24 or 32 mg per dosage form.
The present invention also relates to products containing as first active ingrediént an atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor (II), as combined preparations for simultaneous, separate or sequential use in the treatment of patients suffering from psychosis, Alzheimer‘s disease or related dementias.
The present invention also concerns the use of an acetylcholinesterase inhibitor (II) for - the preparation of a medicament for enhancing the effect of an atypical antipsychotic agent (I) on cognition in patients suffering from psychosis. :
Conversely, the present invention also concerns the use of an atypical antipsychotic agent (I) for the preparation of a medicament for enhancing the effect of an acetylcholinesterase inhibitor (I) on cognition in patients suffering from Alzheimer's disease or related dementias.
-3- eo
Additionally, the present invention concerns the use of an atypical antipsychotic agent (I) for the preparation of a medicament for reducing adverse effects associated with acetylcholinesterase inhibitors (I) in patients suffering from Alzheimer‘s disease or related dementias. Said adverse effect can be nausea, vomiting, sweating, restlessness or insomnia. Especially interesting is the use of an atypical antipsychotic agent (I) for the preparation of a medicament for improving sleep in patients suffering from
Alzheimer's disease or related dementias while being treated with acetylcholinesterase inhibitors (II).
Finally, the present invention also concerns the use of an acetylcholinesterase inhibitor (II) for the preparation of a medicament for reducing adverse effects associated with atypical antipsychotic agents (I) in patients suffering from psychoses. Said the adverse effect can be extrapyramidal syndrome or tardive dyskinesia.
In all the preceding uses the atypical antipsychotic (I) is preferably risperidone and the acetylcholinesterase inhibitor (II) is preferably galantamine, in particular the (1:1) hydrobromide.
Claims (26)
1. A pharmaceutical composition comprising a carrier and as first active ingredient an ~ atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor (IT), each in an amount producing a therapeutically beneficial effect in patients suffering from psychosis, Alzheimer's disease or related dementias.
2. A composition according to claim 1 wherein said therapeutically beneficial effect is a synergistic effect on the cognitive functioning of patients suffering from : Alzheimer*s disease or related dementias, or the prevention of the further deterioration of cognition in said patients, or the reduction of adverse effects associated with the one of the active ingredients by the other of the active ingredients.
3. A composition according to claim 1 wherein the atypical antipsychotic M is selected from risperidone, 9-hydroxyrisperidone or a Cig.29 alkanoic acid ester thereof, olanzapine, quetiapine, iloperidone or ziprasidone, and the i ~~ acetylcholinesterase inhibitor (II) is selected from galantamine, rivasti griine or donepezil.
4. A composition according to claim 3 wherein the amount of each of the active ingredients is equal to or less than that which is approved in monotherapy with said active ingredient. :
5. A composition according to claim 3 wherein the atypical antipsychotic @ is risperidone and the acetylcholinesterase inhibitor (IT) is galantamine.
!
6. A composition according to claim 5 wherein the amount of risperidone is 05,1, 2, 4, or 6 mg and that of galantamine (as base) is 8, 16, 24 or 32 mg per dosage form.
7. A product containing as first active ingredient an atypical antipsychotic agent oO and as second active ingredient an acetylcholinesterase inhibitor (II), as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from psychosis, Alzheimer‘s disease or related dementias.
g. The use of an acetylcholinesterase inhibitor (ID) for the preparation ofa medicament for enhancing the effect of an atypical antipsychotic agent (I) on cognition in patients suffering from psychosis.
5 9. Theuse of an atypical antipsychotic agent (I) for the preparation of a medicament for enhancing the effect of an acetylcholinesterase inhibitor (II) on cognition in patients suffering from Alzheimer's disease Of related dementias.
10. The use of an atypical antipsychotic agent (I) for the preparation of a medicament for reducing adverse effects associated with acetylcholinesterase inhibitors (ID) in patients suffering from Alzheimers disease Of related dementias.
11. Use according to claim 10 wherein the adverse effect is nausea, vomiting, sweating, restlessness of insomnia.
12. The use of an acetylcholinesterase inhibitor (II) for the preparation ofa medicament for reducing adverse effects associated with atypical antipsychotic agents (I) in patients suffering from psychoses.
13. Use according to claim 12 wherein the adverse effect is extrapyramidal syndrome or tardive dyskinesia.
14. Use according to any one of claims 8 t0 13 wherein the atypical antipsychotic @ is risperidone and the acetylcholinesterase inhibitor (If) is galantamine.
PCT/EP99/07804
15. A substance or composition for use in a method of treating psychosis, Alzheimer's disease or related dementias, said substance or composition comprising as first active ingredient an atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor (II), and said method comprising administering a therapeutically effective amount of said substance or composition to a patient to produce a therapeutically beneficial effect.
16. A substance or composition for use in a method of treatment according to claim wherein said therapeutically beneficial effect is a synergistic effect on the cognitive functioning of patients suffering from Alzheimer's disease or related dementias, or the prevention of the further deterioration of cognition in said patients, or the reduction of adverse effects associated with the one of the active ingredients by the other of the active ingredients.
17. A substance or composition for use in a method of treatment according to claim 15 wherein the atypical antipsychotic (I) is selected from risperidone, 9- hydroxyrisperidone or a C,,,, alkanoic acid ester thereof, olanzapine, quetiapine, iloperidone or ziprasidone, and the acetylcholinesterase inhibitor (II) is selected from galantamine, rivastigmine or donepezil.
18. A substance or composition for use in a method of treatment according to claim 17 wherein the amount of each of the active ingredients is equal to or less than that which is approved in monotherapy with said active ingredient.
19. A substance or composition for use in a method of treatment according to claim 17 wherein the atypical antipsychotic (I) is risperidone and the acetylcholinesterase inhibitor (II) is galantamine. AMENDED SHEET
PCT/EP99/07804
20. A substance or composition for use in a method of treatment according to claim 19 wherein the amount of risperidone is 0.5, 1, 2, 4, or 6 mg and that of galantamine (as base) is 8, 16, 24 or 32 mg per dosage form.
21. A substance or composition for use in a method for the treatment of patients suffering from psychosis, Alzheimer's disease or related dementias, said substance or composition comprising as first active ingredient an atypical antipsychotic agent (I) and as second active ingredient an acetylcholinesterase inhibitor; (II), as a combined preparation for simultaneous, separate or sequential use, and said method comprising administering said substance or composition.
22. A composition as claimed in claim 1, substantially as herein described and illustrated.
23. A product as claimed in ¢laim 7, substantially as herein described and illustrated.
24. Use as claimed in any one of claims 8 to 14, substantially as herein described and illustrated.
25. A substance or composition for use in a method of treatment as claimed in claim or claim 21, substantially as herein described and illustrated.
26. A new composition, a new product, a new use of an inhibitor (II) as defined in claim 8 or claim 12, a new use of an agent (I) as defined in claim 9 or claim 10, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203454 | 1998-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103081B true ZA200103081B (en) | 2002-07-12 |
Family
ID=8234219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103081A ZA200103081B (en) | 1998-10-16 | 2001-04-12 | Therapy for improving cognition. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121131A2 (en) |
| JP (1) | JP2002527469A (en) |
| KR (1) | KR20010072878A (en) |
| CN (1) | CN1367697A (en) |
| AU (1) | AU6472799A (en) |
| BG (1) | BG105302A (en) |
| BR (1) | BR9914419A (en) |
| CA (1) | CA2345767A1 (en) |
| EE (1) | EE200100136A (en) |
| HK (1) | HK1039745A1 (en) |
| HR (1) | HRP20010262A2 (en) |
| HU (1) | HUP0103781A3 (en) |
| ID (1) | ID28441A (en) |
| IL (1) | IL142588A0 (en) |
| NO (1) | NO20011403D0 (en) |
| PL (1) | PL348107A1 (en) |
| SK (1) | SK4592001A3 (en) |
| TR (1) | TR200101082T2 (en) |
| WO (1) | WO2000023057A2 (en) |
| ZA (1) | ZA200103081B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
| DE60238780D1 (en) | 2001-10-30 | 2011-02-10 | Novartis Ag | DEPOT FORMULATIONS OF ILOPERIDONE AND A STAR-TERM POLYMER |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| WO2006065233A1 (en) * | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| WO2005065645A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5930573B2 (en) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | New use of glutaminyl cyclase inhibitors |
| DK2142514T3 (en) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| MX2007008642A (en) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias. |
| CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
| JP6026284B2 (en) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | Inhibitors of glutaminyl cyclase |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| ES2881081T3 (en) | 2013-03-15 | 2021-11-26 | Agenebio Inc | Procedures and compositions to improve cognitive function |
| EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
| CN107810002B (en) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | Extended release pharmaceutical compositions of levetiracetam |
| ES2812698T3 (en) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Glutaminyl cyclase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| EP0515301A3 (en) * | 1991-05-14 | 1993-06-16 | Ernir Snorrason | Improvements in benzodiazepine treatment by cholinesterterase inhibitors |
| JP4640888B2 (en) * | 1997-08-11 | 2011-03-02 | ザ ユニヴァーシティー オブ サウス フロリダ | Nicotine antagonists for neuropsychiatric disorders |
| DK1073432T3 (en) * | 1998-04-14 | 2007-12-17 | Gen Hospital Corp | Use of D serine or D alanine for the treatment of schizophrenia |
-
1999
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/en unknown
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 EE EEP200100136A patent/EE200100136A/en unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/en unknown
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/en not_active IP Right Cessation
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
- 1999-10-12 CN CN99812184A patent/CN1367697A/en active Pending
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/en unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/en not_active Withdrawn
- 1999-10-12 ID IDW20010828A patent/ID28441A/en unknown
- 1999-10-12 PL PL99348107A patent/PL348107A1/en unknown
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/en not_active Application Discontinuation
- 1999-10-12 IL IL14258899A patent/IL142588A0/en unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/en unknown
- 2001-03-20 NO NO20011403A patent/NO20011403D0/en not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/en not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
-
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2345767A1 (en) | 2000-04-27 |
| BG105302A (en) | 2001-11-30 |
| CN1367697A (en) | 2002-09-04 |
| IL142588A0 (en) | 2002-03-10 |
| AU6472799A (en) | 2000-05-08 |
| SK4592001A3 (en) | 2001-12-03 |
| JP2002527469A (en) | 2002-08-27 |
| HK1039745A1 (en) | 2002-05-10 |
| PL348107A1 (en) | 2002-05-06 |
| WO2000023057A2 (en) | 2000-04-27 |
| KR20010072878A (en) | 2001-07-31 |
| HUP0103781A2 (en) | 2002-03-28 |
| ID28441A (en) | 2001-05-24 |
| EP1121131A2 (en) | 2001-08-08 |
| HRP20010262A2 (en) | 2002-06-30 |
| NO20011403L (en) | 2001-03-20 |
| TR200101082T2 (en) | 2001-09-21 |
| BR9914419A (en) | 2001-06-26 |
| WO2000023057A3 (en) | 2000-07-27 |
| HUP0103781A3 (en) | 2003-09-29 |
| EE200100136A (en) | 2002-06-17 |
| NO20011403D0 (en) | 2001-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200103081B (en) | Therapy for improving cognition. | |
| KR101125462B1 (en) | Pharmaceutical formulations of modafinil | |
| US20030013689A1 (en) | Method for treating pain | |
| DE60009697T2 (en) | USE OF 1- [4- (5-CYANOINDOL-3YL) BUTYL] -4- (2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE AND ITS PHYSIOLOGICAL ACCEPTABLE SALTS FOR THE TREATMENT OF BIPOLAR DISEASES AND MANIA | |
| RU93004484A (en) | DERIVATIVES OF PYRAZOLES, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
| KR20080014002A (en) | Dispersible tablet | |
| CZ284363B6 (en) | The application of anticonvulsive agent being selected from a group containing carbamazepine and oxcarbazepine | |
| IL158903A0 (en) | Use of sulodexide for the treatment of inflammatory bowel disease | |
| BG63933B1 (en) | Inoculation quinolone medicamentous form | |
| JPH08245417A (en) | Pharmaceutical noninorganic salt solution for intranasal administration | |
| SK8262001A3 (en) | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males | |
| HU206833B (en) | Process for producing pharmaceutical compositions containing calcitoninogen-like peptide-amide or pharmaceutically acceptable salt thereof for treating erective disfunctions | |
| CN1317030C (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists | |
| JP6836825B2 (en) | Methods for improving the water solubility of water-insoluble or slightly water-soluble drugs | |
| KR101258422B1 (en) | Novel triglyceride reducing agent | |
| HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
| JP2009007329A (en) | Composition for preventing or treating disease or state involving cognitive impairment | |
| JP2012500248A (en) | Treatment of anxiety disorder | |
| JP2022528481A (en) | Pharmaceutical compositions of pimozide and methotrexate, and their use | |
| JPH0678227B2 (en) | Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide-containing formulations, stabilization method and stabilized formulations | |
| EP0671908B1 (en) | Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers | |
| JPH07188023A (en) | Vascularization inhibitor | |
| NZ321370A (en) | Polymorphic forms of a growth hormone secretagogue | |
| RU2001113270A (en) | TREATMENT AIMED AT IMPROVEMENT OF COGNITIVE ABILITY | |
| CA2187651A1 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion |